SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply following reports of an upcoming partnership with Novo Nordisk to sell obesity drugs, signaling an end to their prior legal dispute. The unexpected collaboration has the community actively discussing the potential for a significant short squeeze, given the stock's high short interest, and anticipating substantial upside.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership announcement with Hims & Hers to distribute its obesity drugs, ending a prior feud. The community is actively discussing the substantial surge in Hims' stock compared to Novo Nordisk's more modest reaction, raising questions about the deal's implications for the GLP-1 market and competitive landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a sharp rebound, driven by the departure of a controversial FDA official, which the community speculates could pave an easier regulatory path for its Huntington's disease gene therapy and is currently fueling a short squeeze.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is gaining significant attention and volume following new listings on major exchanges, positioning it as the utility token for the Solana Mobile "Seeker" smartphone ecosystem. The community is actively discussing breaking key resistance levels with strong bullish conviction, though some caution about potential selling pressure from recent airdrops and staking unlocks.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is drawing significant attention as traders position for a decline in crude prices, anticipating that current Middle East geopolitical tensions and the Strait of Hormuz situation will eventually de-escalate, unwinding oil's recent fear premium.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is experiencing a rapid price run-up, leading to polarized community discussions between those anticipating a major AI-driven breakout with connections to the Base network, and others cautioning about potential pump-and-dump dynamics given its past performance and reported red flags.

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro is trending sharply following positive news from its partner uniQure's Huntington's disease gene therapy, highlighting ClearPoint's essential precision delivery technology and fueling community excitement about its diverse pipeline in neurological treatments.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to significant community optimism following reports of Dr. Vinay Prasad's departure from the FDA, which many believe will foster a more permissive regulatory environment for gene therapies. This development, coupled with CEO Doug Ingram's announced retirement, is fueling M&A speculation and anticipation for upcoming DM1 and FSHD data.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals ($DAWN) is trending after agreeing to be acquired by Servier for $21.50 per share in cash, a deal valued at approximately $2.5 billion that offers a significant premium. The community is celebrating substantial gains, with many noting how patience and conviction paid off amidst previous buyout speculation and a recent massive volume spike.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders PR Newswire BRANFORD, Conn., March 5, 2026...

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates PR Newswire BRANFORD, Conn., Feb. 27, 2026...

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash Azitra, Inc. Announces Addition of MD Anderson Cancer...

Azitra, Inc. to Present at BIO Investment & Growth Summit

Azitra, Inc. to Present at BIO Investment & Growth Summit Azitra, Inc. to Present at BIO Investment & Growth Summit PR Newswire BRANFORD, Conn., Feb. 19, 2026 BRANFORD, Conn., Feb. 19, 2026...

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting PR...

<ul class="summary-bullets"><li>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.</li><li>The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.</li><li>Some of the symptoms of ichthyosis vulgaris include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or stomach.</li></ul>Azitra Inc. (AZTR) on Monday announced positive preclinical data for its ATR-01 program, which is designed to treat ichthyosis vulgaris, a skin disorder that most often appears in early childhood.<h2 class="st-heading-2">Ichthyosis Vulgaris Affects 1.3 Million People In The U.S.</h2>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder. The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.<blockquote>“We are optimistic that this innovative, topically delivered treatment option has the potential to directly address the disease pathophysiology. We look forward to further updates on this program in 2026, including details around a path to first-in-human studies."– Francisco Salva, CEO, Azitra</blockquote><a href="https://stocktwits.com/symbol/AZTR">Azitra shares</a> soared more than 56% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Is Ichthyosis Vulgaris?</h2>Ichthyosis vulgaris is a common skin disorder that causes dry, scaly skin. Some of the symptoms include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or the stomach,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://my.clevelandclinic.org/health/diseases/21069-ichthyosis-vulgaris">according</a> to the Cleveland Clinic. Some of the options available to manage these symptoms include frequent moisturization using topical exfoliants or oral retinoids in severe cases.Get updates to this story developing <a href="https://stocktwits.com/news-articles/markets/equity/azitra-shares-soar-premarket-positive-preclinical-data-ichthyosis-vulgaris/ch6CHUIR3Ym">directly on Stocktwits</a>.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-up-major-earnings-week/ch6CM53R3Yh">Dow Futures Edge Up As Investors Turn Attention To Major Earnings Week: AMZN, BA, NVDA, ZION Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Azitra Shares Soar Pre-Market: What’s Driving The Surge?

Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.

Equity

Azitra had its best trading day in more than seven months on Wednesday after disclosing that the first patient had been dosed in its Phase 1/2 trial of ATR04-484, a topical live biotherapeutic being developed to treat rashes caused by EGFR inhibitor (EGFRi) cancer therapies.The stock closed Wednesday up 35.9% at $1.03, before slipping 2.4% in after-hours trading.ATR04-484, which has a fast-track designation from the FDA, is designed to address EGFRi-associated rash, a side effect that affects an estimated 150,000 people in the U.S. each year.&nbsp;These rashes are one of the most common and disruptive side effects of EGFRi cancer drugs, occurring in up to 80% of patients and often severe enough to interrupt treatment.“Dosing the first patient is an important milestone in the advancement of ATR04-484 as a potential treatment for EGFRi-associated rash,” said CEO Francisco Salva. He noted the therapy could help reduce the dermatologic toxicities that limit&nbsp;the use of targeted cancer therapies such as those for lung and colorectal cancers.The randomized, double-blind, vehicle-controlled Phase 1/2 study will evaluate ATR04-484’s safety, tolerability, and efficacy in adult patients, measuring endpoints such as rash severity, itch, and pain.&nbsp;The drug is based on an engineered strain of Staphylococcus epidermidis, designed to reduce IL-36γ and S. aureus levels, both of which are elevated in EGFRi-related rashes.Beyond ATR04-484, Azitra is also advancing ATR-12 for Netherton syndrome, a rare and life-threatening genetic skin disease with no approved therapies. Both programs stem from the company’s dermatology platform, which leverages a microbial strain library and artificial intelligence to identify new drug candidates.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,657% surge in 24-hour message volume.One user said that Azitra shares had been “holding pretty strong,” while others pointed to the surge in trading activity.&nbsp;<stembedurl>https://stocktwits.com/TheStocksDoc/message/626774494</stembedurl><stembedurl>https://stocktwits.com/Thunderman/message/626784109</stembedurl>Wednesday’s turnover reached 110.7 million shares, more than 800 times the stock’s average daily volume of about 132,000.<a href="https://stocktwits.com/symbol/AZTR">Azitra’s stock</a> has declined 63.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra’s stock (AZTR) has declined 63.7% so far in 2025. (Photo credit: Getty Images)

Azitra Stock Scores Best Day In 7 Months After First Patient Dosed In Cancer-Linked Skin Rash Trial

The FDA has granted the program Fast Track status, aiming to address rashes that affect roughly 150,000 U.S. patients each year.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday morning after it announced two developments on Tuesday. The firm said the US Patent and Trademark Office (USPTO) has granted a patent that covers future potential pipeline candidates for indications including atopic dermatitis.Apart from this, the company also announced three additional newly allowed patents in three countries, including the US, Canada, and China. Following the announcement, the stock had closed over 200% higher on Tuesday. However, a large portion of the gains were pared in Wednesday’s pre-market session with the stock losing over 75% ahead of the market open.Following the development, the stock gained a lot of traction on Stocktwits. Tuesday’s page views for the symbol on Stocktwits stood at 220x their daily average of the previous month. Total user messages on the Azitra symbol page grew from a handful per day to over 1,000 on Tuesday while total number of users with the stock symbol on their watchlist grew by nearly 1,000 to roughly 1,600 as of Wednesday morning.The firm expressed optimism about its new patents. Azitra’s COO and co-founder Travis Whitfill pointed out that atopic dermatitis affects approximately 16.50 million people in the United States. “There are numerous diseases associated with filaggrin deficiency, and the newly issued U.S. patent extends our protection to include a major market in the U.S., atopic dermatitis, particularly those with mild to moderate disease. Additionally, the new patent allowances in China and Canada extend our IP strength globally,” he said.Meanwhile, the firm also announced a $10 million fundraise via common shares and warrants priced at $1.50. The company said it intends to use the net proceeds from this offering for working capital and general corporate purposes, but the dilution is weighing heavily on shares Wednesday morning.Stocktwits users are chatting about the stock’s sudden dip after Tuesday’s optimism. One user named “dt2011” pointed out the benefits of taking profits when opportunity allows.<figure class="image"><a href="https://stocktwits.com/dt2011/message/580521550"><img style="aspect-ratio:815/263;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_9_18_29_AM_8c732d9994.png" alt="Stocktwits user dt2011's post on Azitra Inc" width="815" height="263"></a><figcaption>Stocktwits user dt2011's post on Azitra Inc</figcaption></figure>

Azitra Stock Witnesses 220x Page Views On Stocktwits After These Developments 

The stock closed over 200% higher on Tuesday after the firm reported multiple patent wins. Still, investors are not very enthused with the company’s latest public offering worth $10 million

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

AZTR
Azitra Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AZTR News

AZTRAzitra Inc